Evaxion Biotecch (EVAX)
(Delayed Data from NSDQ)
$3.15 USD
-0.15 (-4.57%)
Updated Jul 15, 2024 03:58 PM ET
After-Market: $3.09 -0.06 (-1.88%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Evaxion Biotech AS Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 6 | 13 | 32 | 6 | 10 |
Receivables | 1 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 1 | 4 | 1 |
Total Current Assets | 8 | 17 | 35 | 11 | 11 |
Net Property & Equipment | 4 | 5 | 5 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 13 | 22 | 40 | 12 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 1 | 1 | 2 | 1 |
Total Current Liabilities | 7 | 4 | 4 | 5 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 8 | 8 | 1 | 0 | 0 |
Non-Current Capital Leases | 2 | 2 | 2 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18 | 14 | 8 | 5 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 6 | 4 | 4 | 3 | 2 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -108 | -73 | -50 | -27 | -16 |
Other Equity | 97 | 77 | 79 | 32 | 23 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -5 | 8 | 32 | 7 | 9 |
Total Liabilities & Shareholder's Equity | 13 | 22 | 40 | 12 | 11 |
Total Common Equity | -5 | 8 | 32 | 7 | 9 |
Shares Outstanding | 4.00 | 2.30 | 2.20 | NA | NA |
Book Value Per Share | -1.18 | 3.61 | 14.75 | 0.00 | 0.00 |
Fiscal Year End for Evaxion Biotech AS Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 6 | -99,999 | 7 |
Receivables | NA | NA | 1 | NA | 1 |
Notes Receivable | NA | NA | 0 | NA | 0 |
Inventories | NA | NA | 0 | NA | 0 |
Other Current Assets | NA | NA | 2 | NA | 3 |
Total Current Assets | NA | NA | 8 | NA | 11 |
Net Property & Equipment | NA | NA | 4 | NA | 5 |
Investments & Advances | NA | NA | 0 | NA | 0 |
Other Non-Current Assets | NA | NA | 0 | NA | 1 |
Deferred Charges | NA | NA | 0 | NA | 0 |
Intangibles | NA | NA | 0 | NA | 0 |
Deposits & Other Assets | NA | NA | 0 | NA | 0 |
Total Assets | NA | NA | 13 | NA | 17 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | NA | 0 |
Accounts Payable | NA | NA | 3 | NA | 2 |
Current Portion Long-Term Debt | NA | NA | 0 | NA | 0 |
Current Portion Capital Leases | NA | NA | 0 | NA | 0 |
Accrued Expenses | NA | NA | 0 | NA | 0 |
Income Taxes Payable | NA | NA | 0 | NA | 0 |
Other Current Liabilities | NA | NA | 4 | NA | 2 |
Total Current Liabilities | NA | NA | 7 | NA | 4 |
Mortgages | NA | NA | 0 | NA | 0 |
Deferred Taxes/Income | NA | NA | 0 | NA | 0 |
Convertible Debt | NA | NA | 0 | NA | 0 |
Long-Term Debt | NA | NA | 8 | NA | 8 |
Non-Current Capital Leases | NA | NA | 2 | NA | 2 |
Other Non-Current Liabilities | NA | 0 | NA | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | NA | 0 |
Total Liabilities | NA | NA | 18 | NA | 14 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | NA | 0 |
Common Stock (Par) | NA | NA | 6 | NA | 4 |
Capital Surplus | NA | NA | 0 | NA | 0 |
Retained Earnings | NA | NA | -108 | NA | -84 |
Other Equity | NA | NA | 97 | NA | 82 |
Treasury Stock | NA | NA | 0 | NA | 0 |
Total Shareholder's Equity | NA | NA | -5 | NA | 3 |
Total Liabilities & Shareholder's Equity | NA | NA | 13 | NA | 17 |
Total Common Equity | 0 | 0 | -5 | 0 | 3 |
Shares Outstanding | 5.40 | 5.20 | 4.00 | 2.70 | 2.50 |
Book Value Per Share | 0.00 | 0.00 | -1.18 | 0.00 | 1.02 |